Adoptive immunotherapy: good habits instilled at youth have long-term benefits

Many recent advances in basic cell biology and immunology are a harbinger of progress in adoptive cell therapy (ACT) including (1) the finding that host lymphodepletion enhances engraftment and efficacy, (2) the recognition that in vitro T cell functions may not correlate with in vivo efficacy, and (3) the development of advanced ex vivo culture methods to expand lymphocytes to therapeutically effective numbers. In this article, we focus on the development of artificial antigen presenting cells (aAPCs) in our laboratory and their applicability to augment ACT protocols. We also describe how aAPCs can be used to broaden ACT to treat patients with a wide variety of cancers, chronic infectious diseases, and autoimmune manifestations.

[1]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[3]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[4]  S. Grupp,et al.  Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. , 2003, Blood.

[5]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[6]  B. Levine,et al.  Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. , 2004, Blood.

[7]  C. June,et al.  Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 , 2008, The Journal of Immunology.

[8]  T. Mak,et al.  The development of inflammatory TH-17 cells requires interferon-regulatory factor 4 , 2007, Nature Immunology.

[9]  C. June,et al.  Clinical application of expanded CD4+25+ cells. , 2006, Seminars in immunology.

[10]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[11]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[12]  L. Emens.  A New Twist on Autologous Cancer Vaccines , 2003, Cancer biology & therapy.

[13]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[14]  J. O’Shea,et al.  TH-17 differentiation: of mice and men , 2007, Nature Immunology.

[15]  L. Harrington,et al.  Expanding the effector CD4 T-cell repertoire: the Th17 lineage. , 2006, Current opinion in immunology.

[16]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[17]  C. June,et al.  Costimulation Light: Activation of CD4+ T Cells with CD80 or CD86 Rather Than Anti-CD28 Leads to a Th2 Cytokine Profile1 , 2000, The Journal of Immunology.

[18]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[20]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[21]  G. Trinchieri,et al.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.

[22]  J. Dick,et al.  Distinct classes of human stem cells that differ in proliferative and self-renewal potential , 2001, Nature Immunology.

[23]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[24]  Bruce L. Levine,et al.  Antiviral Effect and Ex Vivo CD4+ T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation , 1996, Science.

[25]  H. Zemon.  An artificial solution for adoptive immunotherapy. , 2003, Trends in biotechnology.

[26]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.

[27]  R. Figlin,et al.  Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Bluestone,et al.  How do CD4+CD25+ regulatory T cells control autoimmunity? , 2005, Current opinion in immunology.

[29]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[30]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[31]  Michael Milone,et al.  Genetic engineering of T cells for adoptive immunotherapy , 2008, Immunologic research.

[32]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[33]  C. June,et al.  Programming the next generation of dendritic cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  P. Hammerman,et al.  The Pim kinases control rapamycin-resistant T cell survival and activation , 2005, The Journal of experimental medicine.

[35]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[36]  C. June,et al.  A translational bridge to cancer immunotherapy , 2003, Immunologic research.

[37]  C. June,et al.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  S. Ziegler,et al.  Isoform-specific inhibition of RORα-mediated transcriptional activation by human FOXP3 , 2009, The Journal of Immunology.

[39]  M. McGeachy,et al.  Review Th17 Cell Differentiation: the Long and Winding Road , 2022 .

[40]  David E. Anderson,et al.  IL-21 and TGF-β are required for differentiation of human TH17 cells , 2008, Nature.

[41]  B. Levine,et al.  CD28 Costimulation Is Essential for Human T Regulatory Expansion and Function1 , 2008, The Journal of Immunology.

[42]  J. O’Shea,et al.  T(H)-17 differentiation: of mice and men. , 2007, Nature immunology.

[43]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[44]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[45]  C. June,et al.  Adoptive T cell therapy for cancer in the clinic. , 2007, The Journal of clinical investigation.

[46]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[47]  B. Levine.  T lymphocyte engineering ex vivo for cancer and infectious disease , 2008 .

[48]  B. Weber,et al.  Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens , 2006, In Vitro Cellular & Developmental Biology - Animal.

[49]  H. Pandha,et al.  Immunotherapeutic potential of whole tumour cells , 2002, Cancer Immunology, Immunotherapy.

[50]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[51]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[52]  D. Gabrilovich,et al.  Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer , 2006, Cancer and Metastasis Reviews.

[53]  S. Rosenberg,et al.  CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells , 2005, The Journal of Immunology.

[54]  J. Wagner,et al.  Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[55]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[56]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[57]  P. Blair,et al.  The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. , 1998, Seminars in immunology.

[58]  Terry B. Strom,et al.  IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.

[59]  A. Houghton,et al.  Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.

[60]  J. Gordan,et al.  Universal tumor antigens as targets for immunotherapy. , 2002, Cytotherapy.

[61]  B. Dréno,et al.  Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma , 2002, Cancer Immunology, Immunotherapy.

[62]  S. Ziegler,et al.  Isoform-Specific Inhibition of RORα-Mediated Transcriptional Activation by Human FOXP31 , 2008, The Journal of Immunology.

[63]  B. Levine,et al.  Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging , 1997, Immunological reviews.

[64]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[65]  C. Rooney,et al.  Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.

[66]  C. June,et al.  Extensive Replicative Capacity of Human Central Memory T Cells1 , 2004, The Journal of Immunology.

[67]  B. Levine,et al.  Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells , 2004, Bone Marrow Transplantation.

[68]  G. Trinchieri,et al.  Interleukin-12 and its role in the generation of TH1 cells. , 1993, Immunology today.

[69]  G. Parmiani,et al.  Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1 , 2007, The Journal of Immunology.

[70]  P. Wernet,et al.  Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells. , 2002, Blood.

[71]  V. Kuchroo,et al.  TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.

[72]  D. Porter,et al.  Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[73]  D. Littman,et al.  The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt , 2008, Nature Immunology.

[74]  M. Connors,et al.  Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. , 1997, Journal of immunology.

[75]  H. Fujii,et al.  Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[77]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[78]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  F. Sallusto,et al.  Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells , 2007, Nature Immunology.

[80]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.